GIC invests HK$659m in Bloomage in bet on Botox
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
GIC Pte's private-equity unit has invested HK$659 million (S$119 million) in Hong-Kong listed Bloomage BioTechnology Corporation Ltd, as it taps into China's growing medical cosmetics market.
The investment consists of HK$465 million convertible bonds and HK$194 million new shares at a subscription price of HK$12 each, Singapore's GIC and Bloomage said in a joint statement on Thursday. Bloomage shares surged 8.2 per cent to HK$15 in Hong Kong at 2:55pm.
Share with us your feedback on BT's products and services
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
